Generic Name and Formulations:
Olopatadine (as HCl) 0.6% (665mcg/spray); aqueous nasal spray; contains benzalkonium chloride.
Alcon Laboratories, Inc.
Indications for PATANASE:
Seasonal allergic rhinitis.
2 sprays in each nostril twice daily.
<6yrs: not recommended. 6–11yrs: 1 spray in each nostril twice daily.
Other nasal diseases: not recommended. Avoid eyes. Monitor for nasal mucosal changes. Discontinue if nasal ulceration develops. Pregnancy (Cat.C). Nursing mothers.
Potentiates CNS depression with alcohol, other CNS depressants.
Bitter taste, headache, epistaxis, throat pain, post-nasal drip, cough, UTIs, nasal ulceration, nasal septal perforation, somnolence; children also: upper respiratory tract infection, pyrexia, rash.
Nasal spray pump—30.5g (240 sprays)
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Adjunctive Therapies for Bipolar Disorder Show Promise, Need More Evidence
- Predicting Treatment-Emergent Mania to Tailor Pharmacotherapy in Bipolar Disorder
- Antidepressants Increase Seizure Risk in Youth and Severely Depressed
- Abnormalities of Cortical Thickness in Bipolar Disorder With Auditory Hallucinations
- Prevalence of Major Depressive Disorder Remains High In US Population
- The Way to the Head May Be Through the Gut: Probiotics for Depression
- Suicide-Screening Toolkit Can Help Identify Youths at High Risk for Suicide
- Agoraphobia: An Evolving Understanding of Definitions and Treatment
- Parental Pressure to Diet Linked With Long-term Harm in Adolescents
- Does Access to Medical Cannabis Reduce Risk for Opioid Abuse?
- Suicide Risk After Self-Harm Among Adolescents, Young Adults
- E-Cigarettes Associated With More Harms Than Benefits at Population Level
- Safety, Efficacy of Deep Brain Stimulation for Alzheimer's
- Many Teens Who Use Tobacco Don't Self-Identify as Users
- Evidence of Methylphenidate Abuse: Characterizing Patterns of Use in Pediatric and Adult Populations